On June 02, 2026, Co-Diagnostics Inc CODX announced ongoing advancements in its Ebola PCR project through its collaboration with CoSara Diagnostics. This initiative focuses on creating a pan-Ebola assay that can quickly identify various ebolavirus strains, along with a multiplex assay designed to distinguish between the Sudan, Tai Forest, Zaire, and Bundibugyo ebolaviruses, which are currently linked to outbreaks in Central Africa.
- Market Cap: $26.5 million
- GF Scoreā¢: 46/100, indicating potential weaknesses in financial strength and profitability
- Financial Strength: 4/10, suggesting a moderate level of financial stability
What's Behind the News?
The announcement regarding Co-Diagnostics' Ebola PCR project is significant as it highlights the company's commitment to developing innovative diagnostic solutions in response to global health crises. The dual-assay approach aims to enhance flexibility in responding to outbreaks, potentially aiding non-governmental organizations in their efforts to control the spread of ebolaviruses. This initiative not only showcases the company's technological advancements but also positions it as a key player in the healthcare sector, particularly in the realm of infectious disease diagnostics.
Co-Diagnostics Inc is a molecular diagnostics company that develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). With a market capitalization of $26.5 million, the company operates within the healthcare sector, specifically in the Medical Devices & Instruments industry. Co-Diagnostics has a history of creating low-cost diagnostic systems for various infectious diseases, including tuberculosis, Zika, and hepatitis, and is now expanding its capabilities to include blood-based pathogen assays.
How Is CODX Valued?
Currently, GF Valueā¢ data is not available for Co-Diagnostics. However, the company's price-to-sales (P/S) ratio stands at 15.22, indicating that the stock may be overvalued relative to its sales. The absence of a price-to-earnings (P/E) ratio reflects the company's current financial challenges, as it has reported negative earnings. For more information on CODX's valuation, visit the CODX stock page.
What Does CODX's GF Scoreā¢ Tell Us?
The GF Scoreā¢ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Scoreā¢ values have been found to generate higher long-term returns (backtested 2006-2021).
| GF Scoreā¢ | 46 |
| Financial Strength | 4/10 |
| Profitability | 1/10 |
| Growth | 6/10 |
Co-Diagnostics' GF Scoreā¢ of 46 indicates that the company faces significant challenges, particularly in profitability, where it ranks just 1 out of 10. However, it shows some potential for growth with a rank of 6 out of 10. The financial strength rating of 4 suggests that while there are some stability concerns, the company is not in a dire financial situation. For further insights, visit the CODX stock page.
What Are Insiders Doing with CODX Stock?
There has been no insider buying or selling activity reported in the last 12 months, indicating a lack of insider confidence or engagement in the stock at this time.
What This Means for Investors
Given the current financial metrics and the GF Scoreā¢, Co-Diagnostics appears to be a company facing significant challenges, particularly in profitability and financial strength. Investors should exercise caution and conduct thorough research before making any investment decisions. For the complete analysis, visit the CODX stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is CODX's GF Scoreā¢?
CODX's GF Scoreā¢ is 46, indicating potential weaknesses in profitability and financial strength.
How is CODX valued?
Co-Diagnostics has a price-to-sales (P/S) ratio of 15.22, suggesting that the stock may be overvalued relative to its sales.
What is CODX's P/E ratio compared to historical?
Co-Diagnostics does not currently have a P/E ratio due to negative earnings, reflecting its financial challenges.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
